NCT02744898已完成2 期
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Tolerability Measured Completion of Dose Regimen
研究概览
简要总结
The purpose of this study is to evaluate the safety of treatment with carboplatin and Abraxane in this patient population and determine the nature and degree of toxicities following treatment. The single stage open label Phase II feasibility study is designed to estimate the proportion of patients who can tolerate the proposed regimen for 6 cycles with no more than two dose level reductions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients must have high risk resected stage I disease (papillary serous histology, clear cell histology or carcinosarcoma), advanced stage (III or IV, all histologies) or recurrent endometrial cancer (all histologies). Patients do not need measurable disease and can enroll following surgery.
- •Patients may not have received prior cytotoxic chemotherapy. However, nonplatinum/non-taxane chemotherapy used for radiation sensitization is allowed. Patients may have received prior radiation therapy (including whole pelvic or vaginal brachytherapy), hormonal therapy, or therapy with biologic agents, but such therapy must be discontinued at least 2 weeks prior to entry on this study.
- •If patients underwent surgery, and chemotherapy is indicated after surgery either as adjuvant or to treat residual disease, study treatment should be initiated within 8 weeks of surgery.
- •In patients who have received prior radiation, at least 4 weeks should have elapsed since the completion of radiation therapy involving the whole pelvis or over 50% of the spine. If vaginal brachytherapy is planned with chemotherapy, it should be done before or after completion of chemotherapy treatment.
- •Poorly differentiated histology, uterine papillary serous carcinoma, clear cell carcinoma or carcinosarcoma is acceptable as long as the predominant metastatic component is epithelial (versus sarcomatous).
- •Patients may have synchronous endometrial and ovarian cancer primaries.
- •Patients must have a GOG performance status of 0, 1, or 2
- •Patients must be at least 18 years of age.
- •Patients must understand and willingly sign an approved informed consent, and authorization permitting release of personal health information.
- •Patients must have adequate liver function: AST and ALT ≤ 2.5 X upper limit of normal (ULN), and bilirubin ≤ 1.5mg/dL.
- •Patients must have adequate bone marrow function: platelets ≥ 100,000 cells/mm3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample), hemoglobin > 9.0g/dl and ANC ≥ 1,500 cells/mm
- •Patients must have adequate renal function: creatinine < 1.5 mg/dL is recommended; however, institutional norms are acceptable.
- •Patients must have < grade 2 pre-existing peripheral neuropathy (per CTCAE).
排除标准
- •Other prior malignancies within 3 years, except non-melanoma skin cancers and synchronous ovarian primaries.
- •Eligibility to a higher priority trial for first line or recurrent endometrial cancer (unless patient is unwilling to participate in such a trial).
- •Patients with concomitant medical illness such as serious uncontrolled infection, or uncontrolled angina, which in the opinion of the treating physician, make the treatments prescribed on this study unreasonably hazardous for the patient.
- •Patients who are pregnant or breastfeeding.
- •Patients with third degree or complete heart block are not eligible unless a pacemaker is in place. Patients on medications, which alter cardiac conduction, such as digitalis, beta-blockers, or calcium channel blockers, or who have other conduction abnormalities or cardiac dysfunction could be entered at the discretion of the investigators.
- •Patients with history of myocardial infarct within 6 months before enrollment, New York Heart Association (NYHA) class II or greater heart failure or symptoms suspicious for congestive heart failure are not eligible unless a LVEF in the past 6 months is documented to be 50% or greater. Patients who have had a LVEF (performed for any reason) that is less than 50% in the past 6 months are ineligible.
研究组 & 干预措施
Carboplatin AUC and Abraxane 100mg/m2
Experimental
干预措施: Carboplatin AUC (Drug)
Carboplatin AUC and Abraxane 100mg/m2
Experimental
干预措施: Abraxane (Drug)
结局指标
主要结局
Tolerability Measured Completion of Dose Regimen
时间窗: 24 months
Tolerability for an individual patient will be defined as remaining on the study for 6 cycles with two or fewer dose reductions.
次要结局
- Progression-Free Survival (PFS) at Month 24(Up to Month 24)
- Objective Response Rate (ORR) as Measured by RECIST 1.1 at Month 24(Up to Month 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT00642759Massachusetts General Hospital36
已完成
2 期
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT00466986Southeastern Gynecologic Oncology40
终止
1 期
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckSquamous Cell Carcinoma of the Head and NeckBasaloid Squamous Cell CarcinomaAdenosquamous Cell CarcinomaUndifferentiated CarcinomaNCT00570674Dana-Farber Cancer Institute29
已完成
2 期
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaMalignant MelanomaNCT00483301Mt. Sinai Medical Center, Miami34
已完成
1 期
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast CancerMetastatic Breast CancerNCT03505528EpiAxis Therapeutics8